A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)

NCT00279747 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Juvenile Rheumatoid

Interventions

DRUG: meloxicam 0.25 mg/kg
DRUG: meloxicam 0.125 mg/kg
DRUG: naproxen 10 mg/kg

Sponsor

Boehringer Ingelheim